Independent, exclusively genomics- and precision medicine-focused firm investing in pioneering tools, therapeutics and diagnostics.
San Francisco, CA
Joined March 2016
- Tweets958
- Following149
- Followers913
- Likes587
In @GenomeWeb's #JPM26 coverage, Founding Partner Nick Naclerio and Partner Mara Aspinall explain how focused, treatment‑guiding tests and rapid innovation cycles are pulling the #diagnostics industry forward: genomeweb.com/cancer/advance…
In @PharmaVoice's #JPM26 feature, Founding Partner Nick Naclerio, PhD, points to vaccines as one of the most promising approaches to help prevent recurrence in some of the toughest cancers.
📖 Read the piece: pharmavoice.com/news/pharma-…
Encouraging news from portfolio company @EncodedTx: the FDA granted Breakthrough Therapy Designation to investigational ETX101 for Dravet syndrome—an important step that can help accelerate development in close collaboration with the FDA.
encoded.com/press-releases/e…
#PartnerNews
Exciting news: The FDA granted Breakthrough Therapy Designation to ETX101 based on clinical evidence from the POLARIS Phase 1/2 trials.
This designation is reserved for therapies that show early signs of meaningful improvement and is intended to accelerate development and regulatory review. This marks an important milestone in advancing ETX101 with urgency and care for patients and families living with Dravet syndrome.
Read today’s release for more information: ow.ly/qQNH50XVKtb
#DravetSyndrome
Portfolio company @Precede_Bio secured $83.5M to scale its blood-based epigenomic platform for next-gen precision medicines. Founding Team Member & Partner Wouter Meuleman, PhD, also joined Precede’s Board.
Details: precede.bio/news/seriesb-fin…
#LiquidBiopsy #PartnerNews
We’re proud to share that Precede Biosciences has secured $83.5M in total financing to scale our next-generation precision diagnostics platform.
This capital supports continued growth amid strong commercial traction with leading biopharmaceutical developers advancing the next wave of precision medicines. More broadly, this milestone reflects growing conviction in the need for diagnostics built for target expression and pathway biology, the biomarkers most relevant to next-generation precision medicines, including antibody drug conjugates (ADCs), targeted protein degraders, and other next-generation precision medicines.
We’re grateful for the continued support of our existing investors, including Illumina Ventures, 5AM Ventures, Bristol Myers Squibb, Osage University Partners (OUP), Binney Street Capital, and Lilly Asia Ventures, and excited to welcome new strategic and institutional partners, including Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital LLC, and Alexandria Venture Investments.
We’re also grateful for the commitment and belief of the team at SVB, who support the Precede Bio mission through strategic, non-dilutive financing.
Together, this group adds deep expertise to the Precede mission, a mission to meaningfully impact drug development success rates and ensure patients receive treatments fully aligned to the biology of their disease.
View press release: precede.bio/news/seriesb-fin…
Proud to support portfolio company @AlamarBio on closing an oversubscribed $50M convertible notes financing and welcoming new scientific and board leadership as the team advances precision #proteomics for earlier disease detection.
Release: alamarbio.com/alamar-bioscie…
#PartnerNews
At #JPM2026, several of our exciting portfolio companies will present.
1/12
◾ 2:30 pm: @AlamarBio
◾ 5:30 pm: @EncodedTx
1/13
◾ 11 am: Kallyope
◾ 4:30 pm: @iambic_ai
1/15
◾ 9:30 am: @DELFIDiagnostic
Don’t miss out on hearing from the teams advancing human health's future.
Founding Partner Nick Naclerio, PhD, will moderate the 1/13 San Francisco RESI JPM 2026 panel, Techbio & Synthetic Biology: Engineering Biology for the Next Wave of Innovation.
Panel info: resiconference.com/resi-jpm-…
@LSciNation #RESI #RESIJPM
In a @biocompare article exploring what we can expect for life sciences in 2026, Founding Partner Nick Naclerio and Partner Mara Aspinall shared their predictions for clinical #diagnostics and precision medicine alongside industry leaders.
Read📖: biocompare.com/Editorial-Art…
Founding Partner Nick Naclerio, PhD, will moderate the 12/4 RESI London Seed Funds panel with fund managers to discuss how early capital fuels bold scientific ideas long before later-stage investment.
Panel info: resiconference.com/panels/#s…
@LSciNation #RESI #RESILondon
On 12/3, Partner Mara Aspinall will present in @asuhealth’s Diagnostics Year in Review 2025 webinar. Tune in to learn about the latest #diagnostics data, trends from the past 12 months & what’s to come in 2026.
🔗 Register: docs.google.com/forms/d/e/1F…
Partner Mara Aspinall discusses the rise of alternative sample types in @360DxNews. Non-blood diagnostic samples offer less invasive, more targeted ways to detect disease, offering new possibilities for patients and providers.
360dx.com/business-news/leav…
Congrats to portfolio company Syntax Bio’s:
🏆 Dr. Brad Merrill, 2025 @IllinoisBiotech iCON Innovator Award recipient. Details: mailchi.mp/ibio/announcing-t….
🏆 Dr. Ryan Clarke, recognized on @CrainsChicago 2025 40 Under 40. More info: chicagobusiness.com/awards/m….
#PartnerNews
.@DrugDiscovNews featured four portfolio company leaders' expertise on how multi-omics is transforming and redefining the ways biology is measured, modeled & controlled—making #DrugDiscovery more mechanism-aware and precision-driven.
👉Full article: drugdiscoverynews.com/how-mu…
Founding Partner Nick Naclerio, PhD, will join LinkBridge Investors’ Global Investors Annual Meeting on 11/18 in Newport Beach, CA with leading VCs and investors for panels and 1:1 discussions on emerging market trends and strategies.
Details: linkbridgeinvestors.com/
Congrats to Hepta on unveiling the first multi-omic atlas of #MASH. This breakthrough connects liver pathway biology with cfDNA methylation signatures in blood, creating a non-invasive molecular window into liver health.
📢 businesswire.com/news/home/2…
#PartnerNews
AI is reshaping how we discover drugs and DeepSeq.AI is leading the way. We're proud to welcome them to Illumina Ventures Labs, where they'll use Illumina NGS technology + hyperscaled data to accelerate protein #DrugDiscovery.
🔗 einpresswire.com/article/864…
#Biotech
Congrats to portfolio company @iambic_ai on raising over $100M to advance AI-driven #DrugDiscovery. This funding will accelerate development of its Enchant and NeuralPLexer platforms and expand its pipeline of innovative therapeutics.
iambic.ai/post/iambic-raises…
#PartnerNews
Pleased to announce Iambic has raised $100M+ in an oversubscribed round to accelerate its AI-discovered therapeutics pipeline & platform. Support from new & existing life sci, tech, growth & sovereign wealth investors underscores strong conviction. More: iambic.ai/post/iambic-raises…
Portfolio company Hepta launched from stealth with $6.7M to redefine liver disease #diagnostics with #LiquidBiopsy. Its #AI platform analyzes DNA fragments, detecting fewer false positives than standard tests.
🎉 Congrats, Hepta team!
businesswire.com/news/home/2…
#PartnerNews
Nov. 12-13, @Tech_Networks is hosting The Spatial Biology Revolution 2025.
Joshua Weinstein, PhD, Advisor to portfolio company Cubase Bio, will present on scalable 3D spatial #genomics on Nov. 12 at 9:55 am PT.
Register for the free, virtual event: technologynetworks.com/tn/on…
